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The increasing amount of highly effective treatment options in relapsing forms of multiple sclerosis (MS) requires
innovative clinical trial design strategies. These strategies may encompass the application of adaptive designs as
well as the adoption of innovative primary outcome measurements. The offered advantages would include, among
others, shorter study follow-up periods and reduction in the number of patients either on placebo or on non-suitable
dosages of the small molecules or biological products under examination. Changing the primary endpoint during the
study conduct additionally represents an option, when the primary endpoint originally is either a composite endpoint
of Magnetic Resonance Imaging (MRI) and clinical variables or a unitary endpoint of clinical variables. The new
outcome measurement of no-evidence-of-disease activity (NEDA) – the former disease activity free (DAF) status,
might represent an attractive approach and NEDA may become a new standard for clinical trials in relapsing MS
(RMS), particularly for pivotal Phase III trials, though also earlier phase trials and exploratory clinical research might
benefit from this endpoint. Future studies in RMS could incorporate NEDA as a primary endpoint and utilize the
adaptive design methodology in order to reduce the sample size and the duration of new therapeutic agents’
clinical development.
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References 17Background
Since the commercial availability of disease-modifying
treatments (DMTs) for the treatment of relapsing mul-
tiple sclerosis (RMS), significant changes have occurred
in the diagnosis and management of multiple sclerosis
(MS), with a significant impact on the clinical research
in this area [1]. The year 1993 saw the release of the first
disease-modifying drug, Betaseron® and this was accom-
panied by increased research and attention on the
disease. Since this time, patients have developed an in-
creasingly sophisticated and accurate understanding of
MS [2]. Additionally, the increasing number of clinical
trials has allowed investigators to observe changes in
terms of characteristics and behaviors of clinical trial
populations in RMS [3, 4]. In particular, patient popula-
tions in recent studies are characterized by a lowerdistributed under the terms of the Creative Commons Attribution 4.0
/licenses/by/4.0/), which permits unrestricted use, distribution, and
appropriate credit to the original author(s) and the source, provide a link to
anges were made. The Creative Commons Public Domain Dedication waiver
1.0/) applies to the data made available in this article, unless otherwise stated.
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clinical trials in comparison to the past. These observa-
tions limit the utility of historical data for effect size esti-
mations based upon either the number or time to the
events or other aspects of disease progression as points
of interest. The reasons for observations of improved
placebo response across many indications are variable,
but within RMS this shift might be related mainly to two
factors:
1. The adoption of McDonald criteria that allows
shortening significantly the timeframe from the
status of a clinically isolated syndrome to the
diagnosis of MS [5].
2. The current standard of care of starting treatment
early, which makes nowadays treatment-naïve subjects
available for clinical trials only when they are at a very
early stage of the disease [6–17].
Given these changes in patient phenotype, two main
challenges can be identified when designing a future trial
in MS:
1. The classical clinical endpoints, recommended by
European Medicines Agency’s (EMA’s) Guideline on
clinical investigation of medicinal products for the
treatment of Multiple Sclerosis [18], may not be
sensitive enough to demonstrate additional efficacy
with respect to the current standard treatments in
head-to-head comparison studies. Even if statistically
significant differences are demonstrated within
primary study data sets it could be argued whether
the detected difference would constitute any
clinically meaningful improvement. Clinical
trials with an add-on treatment design might
face similar challenges.
2. The chance of detecting differences with respect
to placebo in a population with low disease activity
is reduced.
3. Any shift during the clinical development with a
clinical trial conducted in Phase II on a study
population with low disease activity towards a
specific population with high disease activity,
such as in a Phase III confirmatory trial, may be
accompanied by incorrect assumptions regarding
the nature of the dose-exposure-response
relationships, erroneous power calculations for
planned sample sizes, and differences in the
hierarchy of primary and secondary measures.
This may also incur potentially significant regulatory
restrictions in the drug label as a consequence of
changes in the patient population and in the
nature of assessments occurring within the
development program.New design strategies are therefore required to handle
this evolution in patient presentation and progression,
given that trial methodologists historically have had
limited choices for a Phase III trial. One standard option
has been to increase the sample size and the number of
subjects on placebo, introducing potential ethical issues
[19]. Alternatively, use of a head-to-head comparative or
add-on treatment study designs, both designs with active
treatment groups, addresses the ethical issue of exposure
to placebo, but adds further challenges due to the ex-
pected small difference in efficacy between two active
treatments using traditional measures. From this original
situation, creative solutions have been sought and
employed which go beyond these two standard options
and resolve some of their inherent shortcomings.
Among others, a strategy of replacement of the
current standard primary endpoints with a new one
could produce an increased level of sensitivity without
the loss of specificity and reliability. In addition, espe-
cially in early exploratory studies, some advantageous
options include:
 Enrichment maneuvers in selecting the patient
population, ensuring high disease activity status,
for example through the use of a run-in period
during which monthly Magnetic Resonance Imaging
(MRI) scans are performed.
 Use of an adaptive design in order to prospectively
allow the change of a dependent variable or
sample size based upon interim information
during the study.
 Use of surrogate MRI markers as primary outcomes,
or as outcomes that can be used for dose selection
purposes antecedent to longer-term studies evaluating
clinical outcomes.
For the purpose of this article, the potential benefits
offered by adaptive study designs and new outcome
measures will be presented in detail.Adaptive study design methodology in the clinical
development of products targeting multiple sclerosis
Adaptive designs have received attention in the last few
years by both the pharmaceutical/biotechnology indus-
tries and health authorities/regulatory agencies. Adaptive
clinical design methodology, and the terminology to
describe this methodology, has evolved over the years
[20]. Interchangeable terms historically have included
adaptive, sequential, flexible, self-designing, multi-stage,
dynamic and response driven models [21]. Differences in
terminology have contributed to inconsistent and con-
fusing perspectives regarding benefits and potential dis-
advantages of these designs.
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adaptive designs represent a diverse methodology with the
common purpose of improving efficacy in the clinical de-
velopment of drugs, with additional advantages in enhan-
cing efficiency by reducing the cost and time components
associated with drug development. Generally aggregated
under the umbrella of “learning phase” versus “confirma-
tory phase” investigations, a portfolio of different adaptive
designs support different objectives, and range in maturity
from decades old methodology (for example, group se-
quential designs) to more recent and relatively underuti-
lized study designs such as the use of seamless Phase II/III
studies [22]. Frequently, combinations of two or more
approaches are encountered as shown in Table 1.
However, debate and discussion have followed the publi-
cation of recent Food and Drug Administration (FDA)
guidance on adaptive designs [23]. While this guidance
recognizes the urgent need for new drug development
tools, and sets a standard template for adaptive designs, it
also emphasizes potential risks in the introduction of bias
through the use of an adaptive study design methodology.
According to the FDA guidance, an adaptive design
should possess three features:
1.) It is a prospectively planned modification of one or
more specified element(s) of study design or
hypotheses.
2.) The modification is performed in a pre-specified
manner based on an interim analysis of data from
subjects in the study, at one or more times during
the trial.
3.) The interim analyses of accumulated study data are
performed at pre-specified time points, in a fully
blinded or unblinded manner, and can occur with
or without formal statistical hypothesis testing.Table 1 Learning phase versus confirmatory phase investigations
Learning Phase Paradigms
• Adaptive dose-finding for toxicity (Bayesian or Frequentist)
• Adaptive dose finding for efficacy (Bayesian or Frequentist)
• Seamless phase I/IIa
Confirmatory Phase Paradigms
• Group sequential
• Sample size re-estimation
• Adaptive randomization based on observed response
• Adaptive randomization based upon covariate
• Enrichment Designs
• Adaptive treatment-switching design
• Adaptive seamless phase II/III
Adaptive hypotheses
• Superiority to non-inferiorityAs opposed to traditional fixed design trials, adaptive
trials use accumulated data to modify some aspects of
the ongoing trial, with the goal of preserving the validity
and integrity of the trial. Frequently, adaptive design
methodology requires a commensurate increases in study
simulations, unique methods of trial management, and
occasionally less than intuitive methods of analyses and
interpretation. It is axiomatic that the complexity of an
adaptive design must not exceed the available infra-
structure to support its design and execution. Low
complexity adaptive designs within an environment of
well-established infrastructure and processes yield the
best prospects for success.
Learning, confirming or both?
The utility of adaptive clinical trial methodology should
be especially seen in the context of exploratory research
and proof of concept trials, although there have been
adaptive trials submitted as a component of marketing
authorization [24]. In a drug development program, pure
exploration is usually the theme in early phase studies,
where the dose-exposure-response relationships are
speculative, and the clinical phenotype of the intended
patient population and the primary efficacy endpoint are
under study. Adaptation for sample size estimation, the
discontinuation of uninformative dosage groups, or en-
richment of the patient sample represent the most
common utilizations. Once preliminary data supports
the Proof-of-Concept, then a large-scale, randomized,
well-controlled and more traditional confirmatory trial
may be pursued.
In the central nervous system (CNS) area there are
examples reported in the literature of drug develop-
ment programs that utilized exploratory adaptive designs
prior to continuing the drug development program or
launching registration trials. A prominent example of this
is acute migraine trials [25]. More complex adaptive de-
signs may include both patient adaptation and dose
adaptation, incorporating the flexibility to re-estimate
the sample size or the selected dose arm(s) [26].
An adaptive design may combine different phases of
clinical trials; for example, the seamless adaptive Phase
II/III design might be envisioned to combine Phase II
and Phase III trials into one trial without a time gap
between the two phases.
Beyond the use of group sequential designs, other adap-
tive design approaches within the neurological spectrum
of disorders are less frequently encountered, although new
entrants, particularly for adaptive randomization pur-
poses, have been recently reported [27]. Adaptive
designs within MS are limited to very few examples as
reported in the literature. Most frequently, the sample
size estimation will be adapted in relation to the base-
line disease activity of a limited group of subjects
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for this purpose [28].
There are, however, some other examples on how the
adaptive design methodology can be applied to clinical
development in MS. One of these is the BOLD study, a
Phase II study with an adaptive, dose-ranging design
[29]. In this study, an adaptive design was chosen to
characterize the dose–response curve of the study drug.
In a first period of study (“Period 1”), three doses of
study drug and placebo were tested for MRI-supported
efficacy. Based on an interim analysis after 3 months of
treatment, two additional active doses for a second
period of the study (“Period 2”) were selected, thus opti-
mizing the overall determination of the dose–response
curve using 5 data points from active treatment doses
along with placebo. The doses were kept blinded. The
use of this design allowed for the determination of the
optimal dose for later Phase III studies. The choice of
placebo as a treatment control was considered essential to
obtain information on the specific versus non-specific
effects of the active treatment, and provided the best way
of evaluating the efficacy, safety and tolerability profiles of
the study drug. The use of an adaptive design strategy
contributed to a significant reduction in placebo exposure,
both in terms of the number of patients and in regards to
study duration, compared to conventional trial models.
The structural and analytic aspects of the study con-
ducted by Selmaj et al. have resemblance to other
studies within neurological conditions such as amyo-
trophic lateral sclerosis (ALS), in which a two-stage
seamless design is utilized in order to incorporate in-
formation regarding dose–response into a subsequent
phase of the investigation [30]. With appropriate modifi-
cations to the design structure and taking into consider-
ation the endpoints and disease features, these data might
be informative for future RMS studies.
An interim change of the primary dependent variable –
use of the No-Evidence-of-Disease Activity [NEDA] status
The FDA guidance mentions the option of adaptation
for endpoint selection based on interim estimates of
treatment effect. Primary endpoint revision usually takes
one of two forms:
(1) Replacement of the designated primary endpoint
with an entirely new endpoint, or
(2) Modification of the primary endpoint by adding
or removing data elements to the endpoint
(e.g., the discrete event types included in a
composite event endpoint).
Therefore, one of the possible endpoint scenarios
uses a composite endpoint instead of a unitary primary
endpoint.The selection of composite endpoints has also been
regarded as “a useful strategy” for registration of
pharmaceuticals in the International Conference on
Harmonisation (ICH) E9 guideline. It has long been
recognized within other therapeutic areas that using a
composite endpoint to enhance prospects for signal de-
tection at a desired level of statistical significance is
often accompanied by potential distortions in the nature
and magnitude of treatment effects. This is primarily re-
lated to an asymmetry in the clinical importance of vari-
ous parameters constituting the composite – i.e., frequent,
less clinically important outcomes can drive the effect of
therapy on any composite [31]. Therefore, the regulatory
requirements for the use of composite endpoints have
been specified by the EMA Committee for Proprietary
Medicinal Products (CPMP) [32].
According to the CPMP document, the use of a com-
posite endpoint in a clinical trial is usually justified if the
following assumptions are respected:
 The individual components of the composite are
clinically meaningful and of similar importance to
the patient [33].
 The expected effects on each component are similar,
based on biological plausibility [34]. Accordingly,
regulatory guidelines also require the use of
components for which it can be assumed that
treatment will beneficially influence them in a
similar way.
 The clinically most important components of
composite endpoints should at least not be affected
negatively (no worsening of the clinical condition as
measured by the component).
As a consequence, regulatory authorities require that
each component of a composite endpoint be analyzed
separately [32] to assist in the interpretation of treatment
effect, even if the composite is statistically significant.
In MS, the disease-activity-free (DAF) status or as
more recently called, the no-evidence-of-disease activity
(NEDA) status, has become a new treatment goal in
daily clinical practice, and is used for decision making
on treatment changes or dose adaptations for current
treatments [35]. NEDA, a composite measure of disease
activity, is currently defined only by 3 parameters:
 Absence of new or enlarging T2 legions or T1
gadolinium-enhancing lesions on MRI.
 Absence of sustained Expanded Disability Status
Scale (EDSS) score progression.
 Absence of any clinical relapse.
The concept of NEDA however, in the combination of
the three variables as listed above or with any additional
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standardization in terms of frequency of assessments
and time period of observation. It is only recommended
that NEDA should be evaluated within a given time
frame of at least 1 year. Under these circumstances, the
NEDA status could be strongly influenced by the dur-
ation of the study, the disease activity present at base-
line, and the frequency of preplanned assessments This
might not only be particularly relevant for the MRI com-
ponent, but also for the clinical components for which
the observation of disease progression is directly in rela-
tionship to the duration of the observational period. In-
deed, a newly published research aimed to establish a
reasonable study duration, as for the predictive value of
this parameter on the long-term disease activity, deter-
mined that with an observational period of 2 years,
NEDA can predict disability at 7 years almost as well as
at 5 years [36].
All 3 parameters defining NEDA status represent dif-
ferent aspects of the disease activity in MS, and con-
sidering them together as representation of the disease
activity increase the sensitivity for detecting evidence
of disease activity, as measurable nowadays. The choice
of NEDA as new outcome measurement, as defined by
a composite of the 3 parameters, increases statistical
precision and efficiency, with beneficial effects on sam-
ple size and study duration. The use of NEDA thus
builds upon a tradition of combining imaging and clinical
parameters in RMS where such combinations are thought
to provide more sensitive outcome measures [37].
However, composite endpoints are associated with
both clinical and biostatistical encumbrances, as shown
already [38] in other therapeutic areas, and emphasized
by the CPMP document [32] as well. It is therefore rea-
sonable to approach their construction in MS with com-
parable caution. Similarly, there are strong arguments in
the recent literature against the use of NEDA as a pri-
mary outcome in clinical trials designated for regulatory
approval purposes [35], even if it’s recognized as an
important goal for treating individual patients with re-
lapsing disease or as a method for selecting the most
appropriate therapy to move forward into confirmatory
trials. In addition, the high variability of disease pro-
gression is neglected by this outcome measure. While
Imitola [39] argues that the concept of NEDA might
not be a realistic outcome for patients with MS, espe-
cially with increasing duration of disease, NEDA might
demonstrate the most utility during the early stages of
relapsing-remitting phase. Indeed, since none of the
current available treatments for RMS represents a “cure”
of the disease, they can only be called disease modifying
treatments (DMTs). DMTs are able only to reduce the fre-
quency and severity of relapses, extend the time intervals
between relapses, and slow progression to permanentdisability [40]. Thus, in the long-term perspective very few
subjects will maintain the status of NEDA, as the disease
will progress even under treatment with DMTs.
Another potential downside in the use of this outcome
lies in the risk of the overall measure being driven by
the event with the greatest level of activity, as opposed to
all events equally, thus violating the symmetry principle
required for composite endpoints. Indeed, the disease
activity free status might represent a reflection of only
MRI defined activity events in trials in RMS where the
composite has been employed, without balancing between
frequency of assessments and the likelihood for observed
findings within the MRI component as compared to the
clinical ones. This risk is discussed by Nixon et al. [41],
who states how some analytical adjustment may be re-
quired to account for the dominance of one component
measure when the overall composite endpoint is driven to
a large extent by MRI outcomes, with minimal contribu-
tion from clinical measures. Such unbalance is further em-
phasized by the number of observational time points used,
if the number of MRI time points is higher than those for
clinical assessments. MRI assessments present a higher
sensitivity than clinical assessments, and disease progres-
sion in terms of clinical assessments is less likely to occur
than disease progression shown by MRI. Indeed, if NEDA
is used as a primary endpoint in a Phase III confirmatory
trial, there is a risk of simply reproducing the results of a
Phase II (MRI-driven) study instead of producing novel
clinical evidence of treatment efficacy, if MRI impact is
not properly weighted, because relapses are rare events
and also disease progression develops very slowly over
time. Although the utility of NEDA status endpoint in
early phase interventional research, as well as in observa-
tional studies, is easily recognizable, further discussion
with health authorities is required to enable inclusion
of this outcome measure in the guidelines on new en-
tities’ clinical development and registration (i.e. poten-
tially pivotal) investigations in RMS. Due to its peculiar
variability, it should be considered that the use of NEDA
as a new primary endpoint from a methodological view-
point may significantly affect sample size estimation, and
it may also introduce a challenge in weighing each compo-
nent in order to avoid unbalance and bias in estimation of
comparative effects. Nevertheless, if properly used, NEDA
would represent a powerful new primary endpoint even in
pivotal Phase III trials, circumnavigating many of the
current statistical challenges inherent in clinical-based
endpoints.
Conclusions
Over the past 20 years, significant changes have occurred
in the diagnosis and management of MS, with a significant
impact on clinical research in this area. Additionally, the
disease-related characteristics of patients presenting for
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ged. The combination of novel DMTs along with a change
in the clinical trials environment, mandate examination of
different clinical trial methodologies. These include struc-
tural modifications in study design as well as the creation
of novel pharmacodynamic and disease-related endpoints.
The advent of new effective therapies in particular has
made the use of placebo in trials lasting more than
6 months difficult to justify clinically, although methodo-
logical rigor precludes the sole use of active control com-
parative trials as a basis for deducing evidence of efficacy
and safety.
Research in RMS is focusing on more sensitive clinical
outcomes and study designs which can more efficiently
evaluate the dose-exposure-response relationship of in-
novative therapies in early phase clinical trials, while
simultaneously reducing the number of patients exposed
to ineffective treatments in clinical programs. We have
identified the recently proposed concept of “No-evi-
dence-of disease-activity” (NEDA) status as a possible
new parameter to be used in conjunction with adaptive
trial designs to investigate the efficacy of new treatment
strategies in RMS. Despite several limitations that the
disease itself imposes for endpoint qualification and des-
pite the prudent approach of health authorities towards
the use of adaptive design for later phase investigations,
the prospect of employing an adaptive design for end-
point selection based on interim estimate of treatment
effect represents an attractive and plausible program op-
tion, even in pivotal Phase III trials. The use of NEDA as
an endpoint deserves further evaluation for future ex-
ploratory studies in MS. Particular attention should be
given to the methodological aspects of this endpoint, in-
cluding the duration of the observational period and the
weighing of each single component. Further methodo-
logical research and modeling are needed, as well as a
full standardization of NEDA as an endpoint, before this
can be universally accepted as a primary endpoint in
future pivotal trials.
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